- PR Newswire•20 days ago
BASEL, Switzerland, February 8, 2017 /PRNewswire/ -- Dr. Reddy's Laboratories Ltd announced today the expansion of its commercial operations in Europe with the introduction of its portfolio of generics ...
- American City Business Journals•21 days ago
Rare-disease drug developer BioMarin Pharmaceutical Inc. sued an Indian drug maker that plans to make and sell a version of one of BioMarin's top-selling drugs. The San Rafael company (BMRN), led by CEO Jean-Jacques Bienaimé, said in a filing Monday in U.S. District Court in New Jersey that a version of the drug Kuvan by Dr. Reddy's Laboratories Ltd. infringes on six BioMarin patents. The Indian company late last year asked the Food and Drug Administration to approve its powder version of Kuvan, saying that BioMarin's patents are invalid, unenforceable or will not be infringed by manufacturing, use or sale.
- Zacks•22 days ago
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 42 cents, down 16% year over year.
DRREDDY.NS : Summary for DR REDDYS LABS INR5 - Yahoo Finance
Dr. Reddy's Laboratories Limited (DRREDDY.NS)
NSE - NSE Delayed Price. Currency in INR
Add to watchlist
|Day's Range||2,845.00 - 2,873.00|
|52 Week Range||2,798.95 - 3,689.85|
|PE Ratio (TTM)||49.66|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|